A Phase 1b Study of Olaratumab, Doxorubicin and Ifosfamide in the Treatment of Patients With Advanced or Metastatic Soft Tissue Sarcoma
Phase of Trial: Phase I
Latest Information Update: 18 May 2018
At a glance
- Drugs Doxorubicin (Primary) ; Ifosfamide (Primary) ; Olaratumab (Primary) ; Mesna
- Indications Soft tissue sarcoma
- Focus Adverse reactions
- Sponsors Eli Lilly
- 10 May 2018 Planned End Date changed from 5 Aug 2019 to 1 Nov 2019.
- 10 May 2018 Planned primary completion date changed from 5 Aug 2019 to 1 Nov 2019.
- 18 Oct 2017 Status changed from not yet recruiting to recruiting.